[mailpoet_sector_follow]

US Broker Ratings

Spyre Therapeutics, Inc. (SYRE): Analyst Consensus Points to a 232.72% Upside Potential

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company, is drawing significant investor attention with its promising pipeline and compelling market potential. Focused on developing innovative..

Theravance Biopharma, Inc. (TBPH) Stock Analysis: Unveiling a 34% Potential Upside for Investors in the Biotech Sector

Theravance Biopharma, Inc. (NASDAQ: TBPH) stands as an intriguing opportunity within the biotechnology sector, not just for its robust revenue growth but also its potential upside..

ATAI Life Sciences N.V. (ATAI) Investor Outlook: 145% Potential Upside in Biotech Space

Investors with an appetite for high-growth opportunities in the biotech sector may find ATAI Life Sciences N.V. (NASDAQ: ATAI) particularly intriguing. The Germany-based clinical-stage biopharmaceutical company..

REGENXBIO Inc. (RGNX): Analyst Ratings Highlight a Promising 213% Upside Potential

REGENXBIO Inc. (NASDAQ: RGNX) is making waves in the biotechnology sector, capturing the attention of investors with its promising pipeline and impressive analyst ratings. Despite facing..

Cullinan Therapeutics, Inc. (CGEM): Exploring a 296% Upside Potential in Biotech

Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a clinical-stage biopharmaceutical firm, is garnering significant investor interest with its promising pipeline of therapies targeting autoimmune diseases and cancer. Headquartered..

Cronos Group Inc. (CRON) Stock Analysis: Navigating Market Challenges with Promising Revenue Growth

Cronos Group Inc. (NASDAQ: CRON), a prominent player in the global cannabinoid market, has been capturing investor attention with its recent financial performance and market positioning...

Iovance Biotherapeutics, Inc. (IOVA): Exploring a 276% Potential Upside in the Biotech Sector

For investors with an eye on the healthcare sector, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) presents a compelling opportunity in the biotechnology industry. With a market capitalization..

Opthea Limited (OPT)

⚠️ No article content returned.

..

Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: A Deep Dive into its 139% Potential Upside

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) stands at the forefront of biotechnology with a mission to revolutionize the treatment of rare and devastating diseases through its innovative..

Maze Therapeutics, Inc. (MAZE) Stock Analysis: Biotechnology Innovator with 25% Upside Potential

Maze Therapeutics, Inc. (NASDAQ: MAZE) has recently been catching the attention of investors, thanks to its strong potential upside and promising pipeline in the biotechnology sector...

LifeMD, Inc. (LFMD) Stock Analysis: Potential Upside of Over 118% for Investors

LifeMD, Inc. (NASDAQ: LFMD), a burgeoning player in the healthcare sector, stands out as a unique investment opportunity, particularly for those interested in the dynamic world..

CeriBell, Inc. (CBLL) Stock Analysis: Unveiling a 159.52% Potential Upside in the Healthcare Sector

CeriBell, Inc. (CBLL), a pioneering entity in the medical devices industry, is poised to capture investor attention with its groundbreaking technology in neurological diagnostics. Headquartered in..

Definitive Healthcare Corp. (DH) Stock Analysis: Navigating the SaaS Healthcare Intelligence Market with a 9.87% Upside

Definitive Healthcare Corp. (NASDAQ: DH) offers a unique proposition within the healthcare sector, serving as a pivotal player in health information services. The company, with a..

Nurix Therapeutics, Inc. (NRIX): Investor Outlook Reveals 224% Potential Upside in Biotech Sector

Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical firm, is making significant strides in the biotechnology sector, specializing in innovative therapies for cancer and inflammatory diseases. With..

MeiraGTx Holdings plc (MGTX) Stock Analysis: Unveiling a Potential 256% Upside in Genetic Medicine

MeiraGTx Holdings plc (NASDAQ: MGTX) is capturing investor interest with its staggering potential upside of 256%. This clinical-stage biotechnology firm, based in New York and listed..

Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a Potential 182.74% Upside in the Biotechnology Sector

In the dynamic world of biotechnology, few companies have captured investor attention like Upstream Bio, Inc. (NASDAQ: UPB). As a clinical-stage biotech firm specializing in treatments..

COMPASS Pathways Plc (CMPS) Stock Analysis: A Biotech with 184% Potential Upside

COMPASS Pathways Plc (NASDAQ: CMPS), a budding player in the healthcare sector, is attracting significant attention from investors due to its innovative approach to mental health..

Verastem, Inc. (VSTM) Stock Analysis: Evaluating a 65.78% Potential Upside Amid Biotech Advances

For investors seeking opportunities in the dynamic biotechnology sector, Verastem, Inc. (NASDAQ: VSTM) presents a compelling case with its significant potential upside of 65.78%. This development-stage..

Semler Scientific, Inc. (SMLR) Stock Analysis: Exploring a 199% Potential Upside in the Healthcare Sector

Investors looking for opportunities in the healthcare sector might want to take a closer look at Semler Scientific, Inc. (SMLR), a company that stands at a..

ArriVent BioPharma, Inc. (AVBP) Stock Report: Analyzing a Potential 108% Upside in the Biotechnology Sector

ArriVent BioPharma, Inc. (AVBP), a rising name in the biotechnology sector, captures investor attention with a striking potential upside of 107.97%, based on analyst ratings. As..

Search

Funds

FTSE 250

Search

Funds

US Broker Ratings

FTSE 100

Funds